Skip to main content
Reveal menu for sighted

Chemistry

VACCINE DISCOVERY

FROM CONCEPT TO CLINIC
Prof. Mario Monteiro
Dr. Mario A. Monteiro, Ph.D.
Full Professor
University of Guelph
 
Editorial Board Member of: 
JENNIFER CRHA presented our most recent vaccine work at the 2018 Canadian Glycomics Symposium in Banff (Alberta, Canada)
JENNIFER CRHA presented our most recent vaccine work at the 2018 Canadian Glycomics Symposium in Banff (Alberta, Canada)
A PLATFORM FOR A MULTI-VALENT DIARRHEA VACCINE
Campylobacter jejuni, Enterotoxigenic Escherichia coli (ETEC) and Shigella sp. are major causes of bacterial diarrhea worldwide. Approaches to C. jejuni and Shigella vaccines include conjugate vaccines in which C. jejuni capsular polysaccharides and Shigella lipopolysaccharides are conjugated to proteins. In the case of ETEC vaccines, most current approaches are based on recombinant proteins that are involved in virulence. Here, the creation of a multi-pathogen vaccine using ETEC proteins as conjugating partners for C. jejuni and Shigella polysaccharides is described. Three vaccines were synthesized in which two C. jejuni polysaccharides were conjugated to two recombinant ETEC adhesins based on CFA/I (CfaEB) and CS6 (CssBA), and LPS from Shigella flexneri was also conjugated to CfaEB. The glycoconjugates were made by first activating the polysaccharides through TEMPO-mediated oxidation [1] (selective/stoichiometric oxidation of primary alcohols) followed by ligation to the ETEC proteins by reductive amination or carbodiimide chemistry. The vaccines were immunogenic in mice as monovalent, bivalent and trivalent formulations. Importantly, functional antibodies capable of inducing hemaglutination inhibition (HAI) of a CFA/I expressing ETEC strain were induced in all vaccines containing CfaEB. These data suggest that conjugate vaccines could be a platform for a multi-pathogen, multi-serotype vaccine against the three major causes of diarrheal disease worldwide.
 
Reference [1] Z. Ma, L. Bertolo, S. Arar, M. A. Monteiro, Carbohy Res. 2011, 346, 343-347.
 
Prof. Mario Monteiro
Carbohydrate chemist Mario Monteiro develops vaccines to thwart pathogenic bacteria. His latest challenge may be his biggest yet — creating a vaccine to fight the gastric bugs that cause havoc in the lives of autistic children.
"In the C. difficile vaccine arena, Matrivax has demonstrated in two distinct preclinical animal models that a vaccine candidate containing both protein and polysaccharide antigens provided superior protection compared to each antigen separately. Development of scalable purification processes for protein and polysaccharide antigens is in progress and GMP production is scheduled to begin in 2018."
Human Vaccines & Immunotherapeutics
Feature article about Prof. Monteiro and his research
Feature article about Prof. Monteiro and his research
He never quite leaves the chemistry lab behind. Even as he heads home each day, part of Prof. Mario Monteiro remains in U of G’s MacNaughton Building with his studies of carbohydrate-based vaccines. And that part of him is still there the next morning. “I do wake up thinking about the research,” he says. “It’s not like I close the door.” 
Recipient of the University of Guelph Inaugural Innovation Award
Recipient of the University of Guelph Inaugural Innovation Award
[Said University of Guelph vice-president research Malcolm Campbell]
“Prof. Monteiro’s research led to the world’s first vaccine that may be capable of controlling both infection and colonization levels from C. difficile."
Speaker at INSTITUTO SUPERIOR TECNICO ChemForum
Speaker at INSTITUTO SUPERIOR TECNICO ChemForum
Prof. Monteiro on Rogers TV News Guelph
The challenges of taking lab concepts to commercialization were the focus of a Talk Local Guelph interview April 4.  Chemistry professor Monteiro, and technology transfer manager David Hobson (P. Eng. DVSc.) explained the complicated path to take an idea to market...
Travelers diarrhea vaccine enters Phase 1 human clinical trial
A vaccine invented at the University of Guelph to protect against Campylobacter jejuni – one of the leading bacterial causes of food-borne illness in the world – has just been approved for human clinical trials by the United States Food and Drug Administration (FDA).
It’s the first U of G technology to reach this testing phase.
“It’s very rare that you have a discovery go this far,” said chemistry professor Mario Monteiro.
Dr. Silvia Borrelli presents our research at the European Carbohydrate Symposium
Dr. Silvia Borrelli presents our most advanced vaccine research at the 19th European Carbohydrate Symposium in Spain. Silvia will describe our vaccines against the gastric pathogens Clostridium difficile and Campylobacter jejuni.
Dr. Silvia Borrelli: 19th European Carbohydrate Symposium in Spain